• In the past quarter, 10x Genomics, Inc. reported first‑quarter 2026 revenue of US$150.84 million, down from US$154.88 million a year earlier, while reducing its net loss to US$13.47 million and basic loss per share to US$0.10.
• The results, which combined a slight sales decline with a meaningfully smaller loss, have sharpened attention on how the company balances growth investments with funding and pricing pressures in the research market.
• Against this backdrop of lower revenue but improved losses, we'll examine how reaffirmed full‑year guidance reshapes 10x Genomics' investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe that single cell and spatial genomics will keep gaining importance in research, and that 10x can convert that into a durable, high margin consumables and software business even while it remains unprofitable. The latest quarter’s slight revenue decline but smaller loss keeps the near term focus on whether reaffirmed 2026 guidance holds, and on the key risk that weaker research funding and pricing pressure could still unsettle that outlook.

The recent launch of Atera, a new in situ spatial platform aimed at large scale, whole transcriptome studies, looks particularly relevant here. It reinforces the catalyst that new products and applications could deepen consumables usage, even as instrument demand and pricing face headwinds. How quickly Atera and other platforms translate into recurring revenue may be a useful counterweight to the concerns raised by the first quarter sales dip.

Yet despite these encouraging product launches, investors still need to watch the risk that tightening research budgets could...

10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.

Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$750 million by 2029, which contrasts sharply with current funding risks and suggests their narrative may need revisiting after this quarter.

Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth as much as 61% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.